ReviewJapanese journal of clinical oncology2023
Advances in treatment of alveolar soft part sarcoma: an updated review.
Review in Japanese journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Sintilimab plus Anlotinib in Patients with Pretreated Locally Advanced or Metastatic Sarcoma: A Prospective, Single-Arm, Phase II Clinical Trial.Cancer immunology research · 2025Trial
- How I treat soft tissue sarcomas.Future oncology (London, England) · 2026Review
- A partial response to atezolizumab in alveolar soft part sarcoma with near-complete resolution of extensive pulmonary metastases: a case report.Frontiers in oncology · 2026Article
- Treatment outcomes of sunitinib and/or pazopanib in advanced alveolar soft part sarcoma: A Turkish Oncology Group (TOG) study.Scientific reports · 2025Article
- Complete Response to Nivolumab and Ipilimumab After Pazopanib Discontinuation in a Seven-Year-Old Girl With Alveolar Soft Part Sarcoma: A Case Report and Literature Review.Cancer reports (Hoboken, N.J.) · 2025Review
- Primary intracranial alveolar soft part sarcomas: a report of seven cases and a pooled analysis of individual patient data.Neurosurgical review · 2025Article
- MAPK-targeted therapies in non-gastrointestinal stromal tumor soft tissue sarcomas: current landscape and future directions.Frontiers in oncology · 2025Review
- Alveolar Soft Part Sarcoma in a 44-year-Old Female: A Case from Uganda.International medical case reports journal · 2025Article
- Imaging-driven diagnosis of retroperitoneal psoas major alveolar soft part sarcoma: a case report.Frontiers in oncology · 2025Article
- Successful Local Control of Orbital ASPS Using VMAT-Based Adjuvant Radiotherapy with Simultaneous Integrated Boost: A 3-Year Follow-Up Case Report.International medical case reports journal · 2025Article
- Recent progress in the clinicopathological characteristics of alveolar soft part sarcoma.Frontiers in medicine · 2025Review
- Novel Therapeutics in Soft Tissue Sarcoma.Cancers · 2024Review
- Ultrasound characteristics of alveolar soft part sarcoma in pediatric patients: a retrospective analysis.BMC cancer · 2024Article
- A framework for target discovery in rare cancers.bioRxiv : the preprint server for biology · 2024Article
- Cheek alveolar soft part sarcoma recurrence at the primary site during follow-up: a case report and review of the literature.BMC oral health · 2024Review
- Biological and therapeutic insights from animal modeling of fusion-driven pediatric soft tissue sarcomas.Disease models & mechanisms · 2024Review
- Establishment and characterization of NCC-ASPS2-C1: a novel patient-derived cell line of alveolar soft part sarcoma.Human cell · 2024Article
- Alveolar Soft Part Sarcoma in the Female Genital Tract: Case Series with Literature Review and SEER Database Analysis.International journal of women's health · 2024Article
- Imaging Features of Alveolar Soft Part Sarcoma: Single Institution Experience and Literature Review.Clinics and practice · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Alveolar soft part sarcoma is a rare neoplasm of uncertain histogenesis that belongs to a newly defined category of ultra-rare sarcomas. The neoplasm is characterized by a specific chromosomal translocation, der (17) t(X; 17)(p11.2;q25), that results in ASPSCR1-TFE3 gene fusion. The natural history of alveolar soft part sarcoma describes indolent behaviour with slow progression in deep soft tissues of the extremities, trunk and head/neck in adolescents and young adults. A high rate of detection of distant metastasis at presentation has been reported, and the most common metastatic sites in decreasing order of frequency are the lung, bone and brain. Complete surgical resection remains the standard treatment strategy, whereas radiotherapy is indicated for patients with inadequate surgical margins or unresectable tumours. Although alveolar soft part sarcoma is refractory to conventional doxorubicin-based chemotherapy, monotherapy or combination therapy using tyrosine kinase inhibitors and immune checkpoint inhibitors have provided antitumor activity and emerged as new treatment strategies. This article provides an overview of the current understanding of this ultra-rare sarcoma and recent advancements in treatments according to the clinical stage of alveolar soft part sarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.